View in EDS

Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.

Saved in:
Bibliographic Details
Title: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Authors: Shemesh CS; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. shemesh.colby@gene.com., Chanu P; Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France., Jamsen K; Certara Strategic Consulting, Princeton, NJ, USA., Wada R; Certara Strategic Consulting, Princeton, NJ, USA., Rossato G; Clinical Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Donaldson F; Safety Science, Roche Products Ltd, Welwyn Garden City, UK., Garg A; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.; Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA., Winter H; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.; Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA., Ruppel J; Bioanalytical Sciences, Genentech Inc., South San Francisco, CA, USA., Wang X; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA., Bruno R; Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France., Jin J; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA., Girish S; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2019 Nov 21; Vol. 7 (1), pp. 314. Date of Electronic Publication: 2019 Nov 21.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31753029
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shemesh+CS%22">Shemesh CS</searchLink>; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA. shemesh.colby@gene.com.<br /><searchLink fieldCode="AU" term="%22Chanu+P%22">Chanu P</searchLink>; Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Jamsen+K%22">Jamsen K</searchLink>; Certara Strategic Consulting, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Wada+R%22">Wada R</searchLink>; Certara Strategic Consulting, Princeton, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Rossato+G%22">Rossato G</searchLink>; Clinical Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Donaldson+F%22">Donaldson F</searchLink>; Safety Science, Roche Products Ltd, Welwyn Garden City, UK.<br /><searchLink fieldCode="AU" term="%22Garg+A%22">Garg A</searchLink>; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.; Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Winter+H%22">Winter H</searchLink>; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.; Present address: Quantitative Pharmacology and Disposition, Seattle Genetics, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ruppel+J%22">Ruppel J</searchLink>; Bioanalytical Sciences, Genentech Inc., South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+X%22">Wang X</searchLink>; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.<br /><searchLink fieldCode="AU" term="%22Bruno+R%22">Bruno R</searchLink>; Clinical Pharmacology, Modeling and Simulation, Genentech/Roche, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.<br /><searchLink fieldCode="AU" term="%22Girish+S%22">Girish S</searchLink>; Department of Clinical Pharmacology Oncology, Genentech Inc., South San Francisco, CA, 94080, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2019 Nov 21; Vol. 7 (1), pp. 314. <i>Date of Electronic Publication: </i>2019 Nov 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31753029
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s40425-019-0791-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 314
    Titles:
      – TitleFull: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shemesh CS
      – PersonEntity:
          Name:
            NameFull: Chanu P
      – PersonEntity:
          Name:
            NameFull: Jamsen K
      – PersonEntity:
          Name:
            NameFull: Wada R
      – PersonEntity:
          Name:
            NameFull: Rossato G
      – PersonEntity:
          Name:
            NameFull: Donaldson F
      – PersonEntity:
          Name:
            NameFull: Garg A
      – PersonEntity:
          Name:
            NameFull: Winter H
      – PersonEntity:
          Name:
            NameFull: Ruppel J
      – PersonEntity:
          Name:
            NameFull: Wang X
      – PersonEntity:
          Name:
            NameFull: Bruno R
      – PersonEntity:
          Name:
            NameFull: Jin J
      – PersonEntity:
          Name:
            NameFull: Girish S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 11
              Text: 2019 Nov 21
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1